Patents Issued in June 2, 2020
  • Patent number: 10668116
    Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: June 2, 2020
    Assignee: Pendulum Therapeutics, Inc.
    Inventors: Colleen Cutcliffe, John S. Eid, James H. Bullard, Marcus F. Schicklberger
  • Patent number: 10668117
    Abstract: The present invention relates to composition derivable from a bifidobacteria, methods and uses thereof, for use in modulating the immune system in a subject by affecting viral action and/or viral effects in said subject. Furthermore, said composition may also be used in reducing the risk of development and exacerbation of chronic respiratory diseases such as asthma and COPD in a subject; preferably by modulating the immune system in the subject by affecting viral action and/or viral effects in said subject.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: June 2, 2020
    Assignee: DUPONT NUTRITION BIOSCIENCES APS
    Inventors: Markus Lehtinen, Sampo Lahtinen, Ronald B. Turner
  • Patent number: 10668118
    Abstract: Provided herein are, inter alia, microbial compositions and methods of using the same. The microbial compositions provided include, inter alia, therapeutically effective amounts of Lactobacillus johnsonii, Faecalibacterium prausnitzii, Akkermansia muciniphila, Myxococcus xanthus and Pediococcus pentosaceus and are particularly useful for methods of treating and preventing inflammatory diseases.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: June 2, 2020
    Assignee: The Regents of the University of California
    Inventors: Susan Lynch, Nikole Kimes, Din Lin, Ricardo Valladares, Kei Fujimura
  • Patent number: 10668119
    Abstract: Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid .sigma.1 protein and expresses a mutated reoviral outer capsid .sigma.3 protein.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 2, 2020
    Assignee: VIROCURE, INC.
    Inventors: Manbok Kim, Randal N. Johnston
  • Patent number: 10668120
    Abstract: A pharmaceutical or cosmetic composition is provided. The composition includes an Indigo Naturalis or Indigo-producing plant extract, for inhibiting Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus. A method of inhibiting Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, is also provided. The method includes contacting a cell with an effective amount of an Indigo Naturalis or Indigo-producing plant extract.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: June 2, 2020
    Assignee: Galderma SA
    Inventors: Yin-Ku Lin, Philippe Andres, Laurent Chantalat
  • Patent number: 10668121
    Abstract: Provided herein are compositions, methods of use thereof and kits comprising same for prophylaxis, alleviating or treating a subject with, or experiencing symptoms associated with, attention deficit disorder/attention deficit hyperactivity disorder (ADD/ADHD) and related disorders. Specifically, the compositions comprise a magnesium mineral, vitamin D and at least one botanical component, in amounts such that the supplement is effective for preventing, alleviating and/or treating a child, teen or adult subject with ADD/ADHD and related disorders or one or more symptoms associated with ADD/ADHD and related disorders.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: June 2, 2020
    Inventor: Yeheskel Tsion
  • Patent number: 10668122
    Abstract: The Toona sinensis extract of the present invention is prepared using supercritical fluid technique, wherein the method includes steps of: (a) drying the leaves of T. sinensis; (b) pulverizing the leaves as particles; and (c) extracting the particles with supercritical carbon dioxide to obtain the T. sinensis extract. This supercritical T. sinensis extract not only can decrease blood sugar level, but also promotes lipid degradation, inhibits the formation of huge lipid droplet and improves the metabolic symptoms. Accordingly, the T. sinensis extract further is able to be prepared as food supplement and pharmaceuticals.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: June 2, 2020
    Assignees: METAL INDUSTRIES RESEARCH & DEVELOPMENT CENTRE, KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Pei-Jung Lien, Chuan-Chia Sun, Tzu-Chen Kuo, Sheng-Chung Yang, Yang-Chang Wu, Fang-Rong Chang, Tusty-Jiuan Hsieh, Yi-Hong Tsai, Ying-Chi Du
  • Patent number: 10668123
    Abstract: Capsicum compositions are described that include biologically active constituents non-capsaicinoids and capsaicinoids in a specific ratio are useful for the treatment and management of cardiometabolic syndrome and associated risk factors, in a subject in need thereof. The capsicum compositions include a capsicum extract which is prepared by extracting capsicum pods by using suitable polar and non-polar solvents. Capsicum compositions include non-capsaicinoid components like saponins and polyphenols such as flavonoids, which along with capsaicinoids effectively reduce risk factors of cardiometabolic syndrome and also reduce oxidative stress on vital body organs by reducing inflammatory and/or oxidative markers. The capsicum compositions inhibit pancreatic lipase enzyme and enhance lipolysis, when administered in an effective amount to a subject in need thereof. Capsicum compositions as described herein are prepared by human intervention and are safe for consumption.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: June 2, 2020
    Assignee: OmniActive Health Technologies Limited
    Inventors: Jayant Deshpande, Vijaya Juturu, Khadija Ghanam, Vandita Srivastava, Jyotish Srivastava, Sudhakar Akella
  • Patent number: 10668124
    Abstract: A method of reducing inflammation in skin is disclosed. The method can include topically applying to skin in need thereof a composition comprising 0.001 wt. % to 5 wt. % of a kakadu plum fruit extract to reduce TNF-? production in human epidermal keratinocytes of the skin, and 0.001 wt. % to 5 wt. % of an acai berry fruit extract to reduce TNF-? production in human epidermal keratinocytes of the skin, wherein topical application of the composition reduces inflammation in the skin.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: June 2, 2020
    Assignee: Mary Kay Inc.
    Inventors: David Gan, Michelle Hines, Javier Aravena, Brian Jones
  • Patent number: 10668125
    Abstract: Disclosed is a peptide of the following (a) or (b): (a) a peptide containing an amino acid sequence including a sequence set forth in any one of SEQ ID NOS: 1, 2, 3, and 4; and (b) a peptide containing an amino acid sequence including a sequence having at least 60% identity with a sequence set forth in any one of SEQ ID NOS: 1, 2, 3, and 4, the peptide having highly-shifted accumulation to pancreatic cancer cells and tissues.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: June 2, 2020
    Assignee: Niigata University
    Inventors: Eisaku Kondo, Ken Saito
  • Patent number: 10668126
    Abstract: The present invention relates to pharmaceutical compositions for treating neoplasias in an animal or human comprised of a carrier and therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin, referred to as opioid growth factor. Also provided are methods of treating neoplasias in an animal or human in need of such treatment, comprising the administration to the animal or human therapeutically effective amounts of a pharmaceutical composition comprised of a carrier and therapeutically effective amounts of at least one neoplasia-treating agent, such as a chemotherapeutic agent or radiation, along with opioid growth factor.
    Type: Grant
    Filed: February 21, 2005
    Date of Patent: June 2, 2020
    Assignee: The Penn State University Research Foundation
    Inventors: Ian S. Zagon, Patricia J. McLaughlin, Jill P. Smith
  • Patent number: 10668127
    Abstract: Methods and compositions for synchronizing the time of insemination in swine are described. More particularly, methods are described for synchronizing the time of insemination by administration of a composition comprising a hormone, wherein the swine is inseminated only one time after administration of the hormone, and wherein there is no heat detection.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: June 2, 2020
    Assignee: United-AH II, LLC
    Inventors: Stephen Kent Webel, Mark E. Swanson
  • Patent number: 10668128
    Abstract: Methods for using a peptide to effectively increase axon growth in both naive and injury-conditioned neurons.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: June 2, 2020
    Assignee: University of South Carolina
    Inventors: Jeffery L. Twiss, Pabitra Sahoo
  • Patent number: 10668129
    Abstract: The present invention relates to the synergistic combination of the short and long Rod-Derived Cone Viability Factors and to methods for treating retinal degenerative diseases.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: June 2, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Thierry Leveillard, John Flannery, Xin Mei, Leah Byrne, José-Alain Sahel, Emmanuelle Clerin-Lachapelle, Junwei Sun, Jean Bennett, Jeannette Bennicelli
  • Patent number: 10668130
    Abstract: The present invention provides formulation/composition comprising phytonutrients with natural chlorotoxins for targeting cancer, infection, inflammation and pain without any side effects and a method for synthesizing the same. The raw materials are cleaned and dried and to prepare coarse powder of 40 mesh size, extracted with solvent (comprising water: alcohol in a ratio of 40:60) in a ratio of 4:1 with overnight soaking. Prior to cold extraction, the mixture is macerated for 4 hours. The mixture is refluxed for 2 hours at 80° C. The addition of ethanol, maceration and refluxing steps are repeated three times and above solvent is added, if required. The residue is checked for complete extraction after every refluxing step. The extract/residue is filtered and concentrated under vacuum. The extract/residue is vacuum tray dried at 70-80° C. for 12 hours. The extract/residue is scraped and dried lumps of the extract/residue are milled. Additional natural product powders are added to the milled powder.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: June 2, 2020
    Inventors: Vivekananda Ramana, Ralph Salvagno
  • Patent number: 10668131
    Abstract: This invention relates to treatment of neuroinjury in a post-acute window or in a chronic period following neuroinjury.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: June 2, 2020
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony Caggiano, Jennifer Iaci
  • Patent number: 10668132
    Abstract: A method for treating, remedying, or preventing psoriasis by administering a therapeutically effective dose of at least one CGRP antagonist compound in a pharmaceutically acceptable formulation. The method for treating, remedying, or preventing psoriasis by administering topically and to the pre-psoriatic rim a therapeutically effective dose of at least one CGRP antagonist compound in a pharmaceutically acceptable formulation.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: June 2, 2020
    Assignee: NEPSONE EHF
    Inventor: Birkir Sveinsson
  • Patent number: 10668133
    Abstract: This invention is directed to the use of a protein hydrolysate, and in particular an egg lysozyme hydrolysate to assist an animal, including a human in overcoming an addition, or by breaking an unwanted habit.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: June 2, 2020
    Assignee: DSM IP ASSETS B.V.
    Inventors: Guillen Santiago Eusebio Fernandez-Reumann, Regina Goralczyk, Joris Kloek, Marijn Christoffel Waander Kroes, Hasan Mohajeri, Guido Alexander Van Wingen, Jonas Wittwer
  • Patent number: 10668134
    Abstract: Provided is a dental pretreatment material for dental tissue regeneration by use of dental pulp stem cells, particularly a dental pretreatment material effectively enabling dental tissue regeneration even by use of dental pulp stem cells of middle-aged or older individuals. The dental pretreatment material is characterized by comprising a serine protease, specifically trypsin. The dental pretreatment material comprising trypsin is used as an injection into a root canal before a root canal filling material comprising dental pulp stem cells and an extracellular matrix is inserted into the root canal as an attempt to regenerate a dental pulp and a dentin. The root canal filling material includes an ALK5 inhibitor, a CCR3 antagonist, or a CCL11 neutralizing antibody.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: June 2, 2020
    Assignee: NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY
    Inventors: Misako Nakashima, Koichiro Iohara, Hideto Watanabe
  • Patent number: 10668135
    Abstract: The present disclosure describes methods for preventing or treating periodontitis or diseases associated with periodontitis. The present disclosure also describes methods of screening for compounds that can be used to prevent or treat periodontitis or diseases associated with periodontitis.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: June 2, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, George Hajishengallis
  • Patent number: 10668136
    Abstract: The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular Lactococcus lactis, of secreted immunodominant antigens.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: June 2, 2020
    Assignee: INTREXON ACTOBIOTICS NV
    Inventors: Pieter Rottiers, Veerle Snoeck
  • Patent number: 10668137
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: June 2, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Walz, Daniel Johannes Kowalewski, Claudia Berlin
  • Patent number: 10668138
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: June 2, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Jens Fritsche, Harpreet Singh, Andrea Mahr, Martina Ott, Claudia Wagner, Oliver Schoor
  • Patent number: 10668139
    Abstract: This invention provides a protein-A or protein-G treated Mycoplasma hyopneumoniae (M.hyo) antigen that is compatible with antigens from other swine pathogens, wherein the M.hyo antigen is an M.hyo culture supernatant.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: June 2, 2020
    Assignee: Zoetis Services LLC
    Inventors: Jeffrey E. Galvin, Gregory P. Nitzel, John Keith Garrett, James R. Kulawik, II, Tracy L. Ricker, Megan Marie Smutzer
  • Patent number: 10668140
    Abstract: Described are non-toxigenic Clostridium difficile strains and spores. Also described are vaccines comprising the Clostridium difficile spores. Further described are methods of preventing or treating a Clostridium difficile infection in a subject in need thereof.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: June 2, 2020
    Assignees: University of South Floirida, Trustees of Tufts College
    Inventors: Xingmin Sun, Abraham Sonenshein
  • Patent number: 10668141
    Abstract: An immunogenic composition containing leucocidin M/F antigen and capable of imparting a toxin-neutralizing activity to a ruminant animal as a subject animal. The immunogenic composition enables prevention of onset or reduction in symptoms of diseases caused by Staphylococcus aureus in ruminant animals. The leucocidin M/F antigen is a protein or peptide having at least a part of the amino acid sequence constituting the leucocidin M protein or a protein or peptide having at least a part of the amino acid sequence constituting the leucocidin F protein. The immunogenic composition may further contain a somatic antigen of Staphylococcus aureus.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: June 2, 2020
    Assignee: Kyoto Biken Laboratories, Inc.
    Inventors: Toshihiro Ito, Taichi Noro
  • Patent number: 10668142
    Abstract: An injectable immunogenic composition comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of Neisseria meningitidis, wherein said capsular saccharides are conjugated to carrier protein(s) and/or are oligosaccharides, and wherein (i) the composition comprises <50 ?g meningococcal saccharide per dose, and/or (ii) the composition further comprises an antigen from one or more of: (a) serogroup B N. meningitidis; (b) Haemophilus influenzae type B; and/or (c) Streptococcus pneumoniae. Saccharide antigens in the compositions are generally conjugated to a carrier.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: June 2, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Paolo Costantino
  • Patent number: 10668143
    Abstract: The invention provides a conjugate of a Neisseria meningitidis serogroup X capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidising a primary hydroxyl group in the capsular polysaccharide, to give an oxidised polysaccharide with an aldehyde group; and (b) coupling the oxidised polysaccharide to a carrier molecule via the aldehyde group, thereby giving the conjugate. The conjugate may be part of an immunogenic composition. This composition may comprise one or more further antigens, particularly capsular polysaccharides from serogroups A, W135, C and Y and conjugated forms thereof. The composition may be in an aqueous formulation. The composition is useful as a vaccine, e.g. for raising an immune response in a mammal. The invention also provides processes for making the conjugate.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: June 2, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Maria Rosaria Romano, Francesca Micoli, Francesco Berti, Roberto Adamo, Paolo Costantino
  • Patent number: 10668144
    Abstract: The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: June 2, 2020
    Inventors: Kim Burgard, Jeremy Kroll, Sarah M. Layton, Volker Ohlinger, Francois-Xavier Orveillon, Stefan Pesch, Michael Dennis Piontkowski, Michael B. Roof, Philip Utley, Eric Martin Vaughn
  • Patent number: 10668145
    Abstract: This invention provides a combination of a first vaccine comprising a porcine circovirus type 2 (PCV2) antigen and a Mycoplasma hyopneumoniae (M. hyo) culture supernatant and a second vaccine comprising a porcine reproductive and respiratory syndrome (PRRS) virus antigen, for treating an animal against an infection with PCV2, an infection with M. hyo, and an infection with PRRS virus, wherein the M. hyo culture supernatant has been separated from insoluble cellular material and is substantially free of both IgG and immunocomplexes comprised of antigen bound to immunoglobulin.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: June 2, 2020
    Assignee: Zoetis Services LLC
    Inventors: Gregory P. Nitzel, Jeffrey E. Galvin, John Keith Garrett, James R. Kulawik, II, Tracy L. Ricker, Megan Marie Smutzer
  • Patent number: 10668146
    Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: June 2, 2020
    Assignee: Valneva Austria GmbH
    Inventors: Robert Schlegl, Michael Möhlen, Jürgen Heindl-Wruss, Michael Weber
  • Patent number: 10668147
    Abstract: Complexes suitable for targeting and killing a human target cell comprising a first polypeptide with a binding structure for binding the complex to the cellular surface receptor CD89 (e.g. with an anti CD89 antibody) presented on the cell surface of the human target cell and a second polypeptide comprising a toxic effector domain, preferably Pseudomonas exotoxin A); to nucleic acid molecules encoding said complexes, vectors, host cells containing the nucleic acids and methods for preparation and producing such complexes; compositions and methods for using said complexes for the treatment of diseases, in particular of cancer diseases like leukemia.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: June 2, 2020
    Assignees: FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V., RHEINISCH-WESTFAELISCHE TECHNISCHE HOCHSCHULE AACHEN
    Inventors: Christoph Stein, Radoslav Mladenov, Bernhard Stockmeyer, Stefan Barth, Lea Christin Schenke, Rainer Fischer
  • Patent number: 10668148
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CXCR3 antibodies. More specifically, there is disclosed fully human antibodies that bind CXCR3, CXCR3-binding fragments and derivatives of such antibodies, and CXCR3-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having CXCR3 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: June 2, 2020
    Assignee: Sorrento Therapeutics. inc.
    Inventors: Barbara A. Swanson, Dingqiu Huang, Heyue Zhou
  • Patent number: 10668149
    Abstract: The present invention relates to combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: June 2, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Parul Doshi, Henk M. Lokhorst, Tuna Mutis
  • Patent number: 10668150
    Abstract: The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: June 2, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Emma S. Cohen, David C. Lowe, Robin Butler, Ian C. Scott, Katherine A. Vousden, Martin D. Strain, Sara Carmen, Elizabeth H. England, Benjamin P. Kemp, David G. Rees, Catherine L. Overed-Sayer, Tomas M. Mustelin, Matthew Sleeman, Kirsty Houslay
  • Patent number: 10668151
    Abstract: This invention relates to antibody-albumin nanoparticle complexes comprising albumin, an antibody with binding specificity for a cancer antigen (e.g. panitumumab), and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro such that the nanoparticle complex has antigen-binding specificity (e.g. EGFR binding specificity), for the purpose of providing cancer (e.g. EGFR-related cancer) treatments in a subject in need thereof.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: June 2, 2020
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10668152
    Abstract: This disclosure provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.
    Type: Grant
    Filed: June 3, 2017
    Date of Patent: June 2, 2020
    Assignees: Bristol-Myers Squibb Company, Celldex Therapeutics, Inc.
    Inventors: Vladimir Coric, Tibor Keler, Thomas Davis
  • Patent number: 10668153
    Abstract: A boron neutron capture therapy system has a neutron beam irradiation device, a patient restraint/placement portion, a three-dimensional diagnostic device, an irradiation table, a position adjustment mechanism, and a control unit. The boron neutron capture therapy system performs position determination with a sufficient degree of accuracy at the time of the boron neutron capture therapy. Further, the control unit, using the movement of the irradiation table, performs collision avoidance processing that changes the movement of the irradiation table before the patient restrained on the patient restraint/placement portion receives injury by colliding with the irradiation port, and thus, collision between the patient and the irradiation port can be avoided.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: June 2, 2020
    Assignees: Fujidenolo Co. Ltd., Cancer Intelligence Care Systems, Inc.
    Inventors: Tsuyako Takeyoshi, Masaru Nakamura, Yoshio Imahori, Hideki Miyazaki, Toshitaka Fujioka, Shinsuke Kato
  • Patent number: 10668154
    Abstract: A method of stabilizing an aqueous protein or antibody formulation is disclosed herein. Additionally, stable pharmaceutical formulations are contemplated which comprise a biologically active protein, a destabilizing concentration of preservative and a stabilizing concentration of osmolyte.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: June 2, 2020
    Assignee: Amgen Inc.
    Inventors: Tiansheng Li, Christopher James Sloey
  • Patent number: 10668155
    Abstract: An embodiment of the present disclosure provides a composition that comprises hyaluronic acid, or its salt or derivative thereof, and an antimicrobial agent, such as zinc citrate, that does not degrade the hyaluronic acid molecule.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: June 2, 2020
    Inventor: Karen K. Brown
  • Patent number: 10668156
    Abstract: Described are solid dispersions of hydrophobic active ingredients and cationic copolymers of N,N-diethylaminoethyl methacrylate and methyl methacrylate in a weight ratio of the monomers of from 35:65 to 55:45. Also described are the preparation and use of such solid dispersions for pharmaceutical dosage forms.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: June 2, 2020
    Assignee: BASF SE
    Inventors: Karl Kolter, Maximilian Angel, Matthias Karl, Silke Gebert, Michael Klemens Mueller
  • Patent number: 10668157
    Abstract: The purpose of the present invention is to provide a polymer gel that can increase drug content ratio and reduce undesirable influence on gel strength and shape stability after the drug release, compared with the conventional techniques. The purpose can be achieved by an anionic drug-containing medical device comprising: (1) an anionic drug; and (2) a copolymer which contains, as constituents, a cationic monomer comprising a condensation product of an alkyl quaternary ammonium compound having a substituted or unsubstituted aralkyl group and (meth)acrylic acid or a salt of the condensation product and a monomer capable of copolymerizing with the condensation product or the salt of the condensation product.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: June 2, 2020
    Assignees: SEED CO., LTD., SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Haruka Obata, Kiyoshi Shoji, Yoshiko Yamazaki, Toru Matsunaga, Takao Sato, Wakiko Asayama, Shinichi Yasueda
  • Patent number: 10668158
    Abstract: The present invention relates to a pharmaceutical composition containing a poorly soluble drug, hyaluronic acid, and a fatty acid, and to a method for preparing the same. The pharmaceutical composition of the present application has excellent stability even for long-term storage and allows a sustained release of the drug, thereby preventing an overdose of the drug and improving the therapeutic efficiency at an effected area.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: June 2, 2020
    Assignee: UNIVERSITY-INDUSTRY FOUNDATION, YONSEI UNIVERSITY
    Inventors: Jaemoon Yang, Jin-Suck Suh, Young Han Lee, Dan Heo
  • Patent number: 10668159
    Abstract: The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: June 2, 2020
    Assignee: Cedars-Sinai Medical Center
    Inventors: Mark Pimentel, Ruchi Mathur, Steve Kanzer, Vince Wacher
  • Patent number: 10668160
    Abstract: An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physicochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delivered by DPI when SAE-CD is used as a carrier.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: June 2, 2020
    Assignee: CyDex Pharmaceuticals, Inc.
    Inventors: James D. Pipkin, Gerold L. Mosher, Douglas B. Hecker
  • Patent number: 10668161
    Abstract: Methods for modifying therapeutic agents such as therapeutic biomolecules, such as proteins for improved oral, rectal or transmucosal delivery, as well as compositions made using such methods and methods of administering such compositions to a subject, are disclosed. Specifically, the therapeutic agents are conjugated to hyperbranched polymers (HBPs), such as hyperbranched polyglycerol (HPG). When such conjugates are administered orally to a subject, the HBP protects the therapeutic agent from the acid environment of the stomach and protease attack in the gastro-intestinal tract, while facilitating the absorption of the therapeutic agent in the higher pH environment of the intestines. The methods and compositions are useful for the improved administration of a variety of therapeutic agents to a subject.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: June 2, 2020
    Assignee: The Regents of the University of California
    Inventors: Yunfeng Lu, Juanjuan Du, Jie Li, Yang Liu
  • Patent number: 10668162
    Abstract: A first aspect of the disclosure relates to a method for preparing cell-targeting conjugates by coupling at least one functional moiety, such as a therapeutic compound, diagnostic compound or chelating agent to a targeting moiety. A second aspect of this disclosure relates to the cell-targeting conjugates obtainable with this method. A third aspect of the disclosure described herein relates to pharmaceutical compositions comprising the cell-targeting conjugates.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: June 2, 2020
    Assignee: LinXis B.V.
    Inventors: Hendrik Jan Houthoff, Augustinus A. M. S. Van Dongen, Robbert Jan Kok, Dennis Christian Johannes Waalboer, Sytze Jan Buwalda, Niels Jurriaan Sijbrandi
  • Patent number: 10668163
    Abstract: An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: June 2, 2020
    Assignee: Tris Pharma, Inc.
    Inventors: Ketan Mehta, Yu-Hsing Tu
  • Patent number: 10668164
    Abstract: The present invention relates generally to glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a spacer containing ((2-oxoethyl)thio)). In an aspect the invention provides oxo-eT linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a ((2-oxoethyl)thio) spacer having the formula (I): (I) wherein: A is a group (C?X)m wherein X is S or O and m is 0 or 1; B is a bond, O, or CH2; and when m is 0, B can also be (C?O); R is a C2-C16 alkylene, C2-C16 heteroalkylene, NH—C(?O)—C2-C16 alkylene, or NH—C(?O)—C2-C16 heteroalkylene, wherein said alkylene and heteroalkylene are optionally substituted by 1, 2 or 3 groups independently selected from COOR? where R? is selected from H, methyl, ethyl or propyl. The invention further relates to immunogenic compositions comprising such glycoconjugates, and to methods for the preparation and use of such glycoconjugates and immunogenic compositions.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: June 2, 2020
    Assignee: Pfizer Inc.
    Inventors: Jianxin Gu, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad, Yu-Ying Yang
  • Patent number: 10668165
    Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: June 2, 2020
    Assignee: IMMUNWORK INC.
    Inventors: Tse-Wen Chang, Chien-Jen Lin, Hsing-Mao Chu